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Abstract
Adolescent non-alcoholic fatty liver disease (NAFLD) isBackground: 
associated with cardiometabolic risk factors. The association between
adolescent NAFLD and a wide range of metabolic biomarkers is unclear. We
have attempted to determine the differences in metabolic profile of adolescents
with and without markers of NAFLD.
We performed cross-sectional analyses in a sample of 3,048Methods: 
participants from the Avon Longitudinal Study of Parents and Children at age
17. We used three indicators of NAFLD: ALT >40 U/l; AST >40 U/l and
ultrasound scan-assessed steatosis. Associations between each measure of
NAFLD and 154 metabolic traits, assessed by Nuclear Magnetic Resonance,
were analyzed by multivariable linear regression, adjusting for age, sex and
BMI.
All three indicators of NAFLD were associated with ~0.5 standardResults: 
deviation (SD) greater concentrations of all extremely large to small very
low-density lipoproteins (VLDL) measures. ALT >40U/l was associated with
~0.5SD greater concentrations of very small VLDLs, intermediate-density
lipoproteins and low-density lipoproteins. Concentrations of most cholesterols,
including remnant cholesterol, all triglycerides and monounsaturated fatty
acids, in addition to glycoprotein acetyls (inflammatory marker), were also
higher in participants with NAFLD.
We have identified differing metabolic profiles betweenConclusions: 
adolescents with and without indicators of NAFLD. These results provide the
foundations for future research to determine whether these differences persist
and result in adverse future cardiometabolic health.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most com-
mon chronic liver disease in adolescents1, with an estimated 
prevalence of 7.6% in the general population, increasing to 
34.2% in obese populations2. NAFLD occurs when at least 5% 
of hepatocytes are infiltrated by fat, in those without significant 
alcohol consumption (<20g/day alcohol for women and 
<30g/day for men)3. NAFLD encompasses both steatosis (accu-
mulation of fat in the liver), without evidence of hepatocyte 
injury, and steatohepatitis (NASH), with hepatocyte injury and 
inflammation, which can progress to cirrhosis and hepatocellular 
carcinoma (HCC)4,5.
The relationship of multiple metabolic pathways, includ-
ing those related to lipids, fatty acids, glycolysis and insulin 
resistance, with NAFLD is complex, as these may be part of a 
‘multiple-hit’ process that results in hepatic steatosis6, or a con-
sequence of NAFLD, and mediators of the effect of NAFLD on 
subsequent adverse cardiometabolic outcomes7. In relation to the 
latter, in adults NAFLD is associated with adverse cardiometa-
bolic risk factors, including insulin resistance, diabetes, and 
dyslipidemia3,8–10 and is therefore described as the hepatic 
component of the metabolic syndrome1,11. Using a population 
of adolescents from the Avon Longitudinal Study of Parents 
and Children (ALSPAC), we recently showed that, even in 
unselected (and otherwise healthy) adolescents, ultrasound scan-
determined hepatic steatosis is associated with higher levels of 
fasting triglycerides, glucose and insulin, and reduced levels 
of HDL cholesterol (HDLc), independent of body mass index 
(BMI) or total body fat mass (TBFM)12.
Given the role of the liver in multiple metabolic pathways, it 
is plausible that adolescent NAFLD is associated with a much 
wider range of circulating metabolomic biomarkers than stand-
ard laboratory lipid (triglycerides and HDL/LDL cholesterol) 
and glucose measurements. Identifying whether this is the case 
could provide valuable measures of disease progression, in 
particular identifying potential mediators of a possible effect of 
NAFLD in early life (adolescence) on subsequent adverse 
cardiometabolic outcomes. Specifically, if we find widespread 
metabolic disruption in adolescents with NAFLD, this could 
indicate those at increased risk of future adverse cardiometa-
bolic outcomes such as type 2 diabetes or cardiovascular disease. 
Previous metabolomics studies of NAFLD have largely had small 
sample sizes (N=30 to N=467)13–19, and have been undertaken in 
select populations, such as obese individuals (the greatest risk 
factor for NAFLD)15,17–19. One exception is a recent study by 
Kaikkonen et al. of unselected (healthy) European adults (mean 
age 42 years) from the Young Finns cohort (N=1,575), which 
examined the association of a range of metabolic biomarkers 
(using the same Nuclear Magnetic Resonance (NMR) platform 
that we have used in this study) with subsequent occurrence of 
NAFLD. They found that increased concentrations of all very 
low-density lipoprotein (VLDL) particle concentrations, except 
very small VLDL particles, and triglycerides in VLDLs, as well 
as several other metabolic traits, were associated with subse-
quent development of fatty liver (odds ratio per 1SD increase 
in log transformed metabolite ranged from 1.38 to 1.51 for the 
VLDL particle concentrations)20.
To the best of our knowledge, no study has yet examined the dif-
ferences in metabolic profile (the collection of lipids and low 
molecular weight metabolites) of adolescents with NAFLD, in 
whom the prevalence of, and years of exposure to risk factors, 
including alcohol, for NAFLD is lower than in adults. We there-
fore aimed to determine whether there was a difference in meta-
bolic profile between adolescents with and without NAFLD, 
using three indicators of NAFLD. Although our study is cross- 
sectional, and therefore cannot determine the direction of asso-
ciations, we were interested in the potential that differences 
in these profiles in adolescents could influence future progression 
and subsequent adverse cardiometabolic outcomes. Therefore, 
we hypothesized that NAFLD would precede metabolic disrup-
tion and treated indicators of NAFLD as the exposures in our 
analyses.
Methods
Study population
We performed cross-sectional analysis in a population of adoles-
cents from ALSPAC. ALSPAC is a prospective cohort of 14,541 
pregnancies with an expected delivery date between 01/04/1991 
and 31/12/1992, recruited from the former Avon area, South-
west England21,22. Of these 14,541 pregnancies, there were 
14,062 live births21. The cohort has been followed up repeatedly 
since birth, including questionnaires and clinical assessment 
from age 7 years19. When the original children were 7 years old, 
an attempt was made to increase the sample size, resulting in the 
addition of 706 pregnancies and 713 children who were alive at 
one year22. The study website contains details of all the data that 
is available through a fully searchable data dictionary: http:// 
www.bristol.ac.uk/alspac/researchers/data-access/data-dictionary/.
Ethical approval for the study was obtained from the ALSPAC 
Ethics and Law committee and the local Research Ethics Com-
mittees. All data was collected and managed following approved 
protocols. The main caregiver initially provided consent for child 
participation and from age 16 years the offspring themselves have 
provided written informed consent. 10,101 (66%) adolescents 
were still eligible for invite to the research clinic at age 17.
Assessment of NAFLD
Ultrasound (USS) assessment of steatosis. Details of the USS 
assessment in ALSPAC have been published previously12. Briefly, 
at the 17- to 18-year follow-up clinic, a pseudo-random sam-
ple (selected based on attendance of clinic between 2008 and 
2011- the period when we had access to staff and resources for 
this substudy) of 1,887 individuals underwent USS of the upper 
abdomen by one of four trained sonographers using a Siemens 
Acuson S2000 USS system. Liver fat was assessed by echogenicity 
during deep inspiration and recorded as present, absent or uncer-
tain following an established protocol23,24. There was a high 
level of agreement between sonographers, assessed immediately 
after training and at six-month intervals (absolute agreement 
>98%). There was no evidence of these participants ever 
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experiencing jaundice, hepatitis or any other liver disease. None 
of the participants were taking medications suggestive of liver 
disease or known to influence liver function.
Blood-based biomarkers. Fasting (overnight or minimum of 
6-hours) blood samples were immediately spun and frozen at 
-80°C. Measurements were assayed between three and nine 
months after samples were taken, with no previous freeze-thaw 
cycles. All assays were completed in the same laboratory at the 
University of Glasgow. Alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) were measured by auto-
mated analyzer with enzymatic methods. We used a threshold of 
>40U/l of ALT/AST as an indicator of NAFLD, as this was 
the most commonly used threshold in adolescent studies based 
on a recent systematic review2.
NMR metabolic profiling
Metabolic profiling was performed using a high-throughput 
proton NMR platform on fasting plasma samples collected at 
the clinic. The 154 metabolic traits included in this analysis 
represent a broad molecular signature of systemic metabolism 
and includes absolute concentrations of 14 lipoprotein subclasses 
(particle concentration, lipid concentrations and composition), 
fatty acids and fatty acid compositions, amino acids, ketone bod-
ies, glycolysis and gluconeogenesis-related metabolic traits25–27. 
The method is based on three molecular windows: LIPO identifies 
lipoprotein subclasses and apolipoproteins, low molecular 
weight molecule (LMWM) identifies amino acids, glucose, 
glycolysis-related metabolites, glycoproteins and ketone bodies 
and LIPID identifies serum lipid constituents such as unsatu-
rated and saturated fatty acids26,27. The protocol is published 
elsewhere25–28.
14 lipoprotein subclasses were identified from this platform26,27. 
Very low-density lipoproteins (VLDL) were subdivided into six 
subclasses based on particle size, from extremely large VLDL 
with particle diameters of above 75.0nm (with a possible con-
tribution of chylomicrons) to very small with average particle 
diameters of 31.3nm. Very large, large, medium and small 
had average diameters of 64.0nm, 53.6nm, 44.5nm and 36.8nm, 
respectively. Intermediate density lipoproteins (IDLs) had a 
mean particle diameter of 28.6nm. The three low density lipopro-
tein subclasses (large, medium and small) had average diameters 
of 25.5nm, 23.0nm and 18.7nm, respectively. There were four 
classes of high density lipoproteins (HDLs) identified, including 
very large with an average diameter of 14.3nm, large with an 
average diameter of 12.2nm, medium with a diameter of 10.9nm 
and small with a diameter of 8.7nm. The mean sizes for VLDL, 
LDL and HDL particles were calculated by weighting the 
corresponding subclass diameters with their particle concen-
trations. Seven traits were determined for each lipoprotein 
subclass: particle concentration, total lipids, total cholesterol, 
phospholipids, triglycerides, free cholesterol and esterified 
cholesterol. Remnant cholesterol was defined as non-HDL and 
non-LDL cholesterol (i.e. VLDL and IDL cholesterol). Fatty 
acids (FAs) were measured as absolute concentrations and as 
percentage of total FAs. There is a high analytical consistency, in 
epidemiological settings, between metabolic measures quantified 
by the NMR metabolomics platform and the concentrations 
obtained from routine clinical chemistry and other analytical 
methods, such as gas chromatography29,30. In addition, the 
consistency of biomarker associations with disease incidence for 
metabolic traits quantified by NMR and two widely used mass 
spectroscopy platforms has been demonstrated29,30.
Other outcomes
We compared associations with standard clinical chemistry 
assessments of lipids (total cholesterol, triglycerides, LDLc and 
HDLc), glucose, insulin and C-reactive protein (CRP). Plasma 
lipids (total cholesterol, HDLc and triglycerides) were assessed 
by modification of the standard Lipid Research Clinics Protocol 
using enzymatic reagents for lipid determination. The Friedewald 
equation was used to calculate LDLc (LDLc= total cholesterol – 
(HDLc+[0.45 x triglycerides]))31. Insulin was assessed by ELISA 
(Mercodia) that does not cross-react with proinsulin and plasma 
glucose by the automated enzymatic (hexokinase) method. 
Plasma glucose and CRP were measured by an automated assay. 
All inter- and intra- CVs for these blood assays were <5%. We 
have previously reported associations of USS-assessed steatosis 
(USS steatosis) with these measurements in this cohort12, but 
present them here in the sub-sample of participants with NMR 
data as a test of agreement between the two analytical approaches. 
It also enables us to examine associations of insulin and CRP 
alongside the wide range of NMR metabolic traits that are the 
focus of this paper.
Covariables
After removing those with high alcohol consumption (see below), 
we considered sex, age and BMI to be the primary confound-
ers in our analyses. Sex was recorded at birth and age at the 
clinic calculated from birth and clinic date. BMI was assessed 
at the clinic at age 17 as weight (kg)/height (m2). Height was 
measured using a Harpenden stadiometer to the last complete 
millimetre. Weight was assessed using a Tanita Body Fat Analyser 
(Model TBF 401A) and was measured to the nearest 50g.
Our a priori assumption was that BMI would be the main 
confounder of the associations of interest, but we explored the 
potential impact of adjusting for additional confounders (physi-
cal activity, caloric intake, ethnicity, maternal education and 
AUDIT score), by comparing results from linear regression 
analyses with adjustment for age, sex and BMI (model 2) to those 
with additional adjustment for each of these confounders in those 
with data for the specific confounder (Figure 1).
Physical activity (PA) was assessed at average age 15 using an 
Actigraph PA monitor (Manufacturing Technology Incorporated, 
Fort Walton Beach, Florida) worn for one week. Data was deter-
mined to be valid if the monitor was worn for at least 10 hours 
on at least three days. Average minutes of moderate to vigor-
ous intensity PA (MVPA) per valid day was calculated based on 
a value of greater than 3600 counts per minute to define 
MVPA32,33. The full protocol for PA assessment is described 
elsewhere34. Caloric intake at average age 13 (kcal) was assessed 
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Figure 1. Correspondence between models adjusted for age, sex and BMI and models adjusted for age, sex, BMI and additional 
confounders for each indicator of NAFLD. Each point represents a metabolic trait and the position represents the difference in mean 
metabolic trait concentrations in standard deviation units adjusted for age, sex and BMI (x-axis) and difference in mean metabolic trait 
concentrations in standard deviation units adjusted for age, sex, BMI and an additional confounder (y-axis). Horizontal grey lines represent 
confidence intervals for x-axis associations, and vertical grey lines represent confidence intervals for y-axis associations. The blue dashed 
line represents the regression line between x-axis and y-axis models for each metabolic trait. R2 indicates goodness-of-fit. A slope of 1 with 
an intercept of 0 (grey dashed line) and all dots sitting on that line (R2 = 1) would indicate exact correspondence, in terms of direction and 
magnitude, between associations of the two models and therefore addition of the confounder to the model does not change magnitude or 
direction of associations. Abbreviations: AST: aspartate aminotransferase; ALT: alanine aminotransferase, USS: ultrasound scan; PA: physical 
activity; SEP: socioeconomic position; AUDIT: alcohol use disorders identification test score; BMI: body mass index.
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by self-completed food diary (with parental help). Methodol-
ogy for dietary assessment is described in detail elsewhere35. 
Ethnicity and maternal highest educational attainment were self-
reported by questionnaire during pregnancy. Socioeconomic 
position was determined using maternal education assessed 
around the time of the participant’s birth. Total body fat mass 
(TBFM, grams) was assessed by dual x-ray absorptiometry 
(DXA), using a Lunar prodigy narrow fan beam densitometer 
(GE Healthcare).
Eligibility criteria
Participants’ alcohol consumption was assessed at mean age 
16.7 and 17.8 years using the Alcohol Use Disorders Identifica-
tion Test (AUDIT)36. A score of 16 or greater at both time points 
indicated harmful drinking. Thirteen participants were removed 
from the USS dataset and 30 individuals were removed from the 
AST/ALT dataset based on these criteria. After removal of these 
individuals, 3,035 participants had data on ALT and AST 
concentrations, metabolic traits and covariates and 1,101 had 
data on USS steatosis, metabolic traits and covariates (Figure 2 
shows the participant flow).
Statistical analysis
We analyzed differences in concentrations of each metabolic 
trait (treated here as the outcome) between those individuals 
with and without NAFLD, as defined by each of the three indi-
cators, using multivariable linear regression models, with model 
1 adjusted for sex and age at assessment and model 2 addition-
ally adjusted for BMI (modelled as a continuously measured 
variable) at assessment. For our main analyses we treated each 
of the three indicators as separate exposures such that for each 
one we compare differences in metabolic traits between those 
with the indicator and those without, even if those without 
one of the indicators (e.g. USS steatosis) had one of the other 
indicators (e.g. high ALT). As several metabolic traits 
displayed a skewed distribution, we performed our regression 
with robust standard errors (SE). We performed our analyses 
with the metabolites in standard deviation [SD] units and also in 
molar concentrations (mostly μmol/l). The former are presented 
in the main paper and allow us to directly compare associa-
tions across all metabolic traits as they are all in the same (SD) 
units. The latter are provided in extended data tables and provide 
outcomes for each trait in clinically meaningful units. Analyses 
Figure 2. Flowchart of recruitment from original birth cohort to study populations for these analyses. Abbreviations: ALT: alanine 
aminotransferase; AST: aspartate aminotransferase.
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were performed using Stata version 14.2 (Stata corp., Texas, USA) 
and R version 3.2.2 (R statistical computing, Vienna, Austria).
As recommended by the American Statistical Association and 
other bodies, we focus our interpretation of the results on the 
size of associations and their confidence intervals (CIs), rather 
than arbitrary p-value thresholds37. However, we do indicate 
those with a multiple-testing corrected p-value so that the role 
of chance can be considered. To account for multiple testing 
and the correlation between metabolic traits, we determined our 
p-value threshold based on principal component analysis using 
all 154 standardized metabolic traits28,38,39. The threshold was 
defined as α/A, where A is the number of principal components 
(PCs) which explain at least 95% of the variance in standardized 
metabolic data and α=0.05. 16 PCs explained at least 95% of the 
variance, so our threshold was p<0.05/16= 0.003, which is 
equivalent to p<0.05 after accounting for multiple testing.
Sensitivity and additional analyses
We repeated analyses after removing those who stated they 
had diabetes at the clinic from our analyses (n=10 for models 
including AST or ALT, n=7 for USS). The reason for this 
sensitivity analysis was that we thought it possible that a diag-
nosis of diabetes and its treatment might be a confounder of our 
associations, but with so few participants with this condition a 
conventional multivariable regression may not fully adjust for 
this. We also removed individuals who were at least seven SD 
above or below the mean value for a metabolic trait to deter-
mine the influence of potential outliers. We repeated analysis 
using enzyme-assessed measures of triglycerides, LDLc, HDLc 
and glucose to check that effect sizes agreed between the two 
methods of quantification (enzymatic and NMR). In addition, 
we adjusted for DXA determined TBFM instead of BMI. Whilst 
in our previous analyses of the impact of USS steatosis on 
conventional lipids (LDLc, HDLc and triglycerides), glucose and 
insulin we found no difference in the impact of adjustment for 
BMI or TBFM (a more direct measure than BMI of fat), we 
wanted to check that that was also the case here with a much 
greater range of metabolic outcomes.
As noted in the Introduction, it is possible that the metabolic 
traits we have assessed are altered prior to liver fat accumulation; 
they may be causes and/or predictors of risk. Indeed, one previ-
ous large general cohort study examined the cross-sectional 
association of the same NMR metabolic traits with USS 
steatosis but assumed that steatosis was the outcome17, rather 
than our hypothesis that NAFLD might result in subsequent 
metabolic disruption. We therefore performed sensitivity anal-
yses to explore the associations of fasting enzyme-assessed 
triglycerides, LDLc, HLDc and glucose assessed at age 15 with 
subsequent NAFLD at age 17 using logistic regression adjusted 
for age, sex and BMI. Fasting blood samples were collected, 
and BMI assessed, at age 15 using the same methodology and 
protocols as at age 17. The clinical laboratory assessment of 
lipids and glucose were also assessed using the same methods as 
those used at the 17 year clinic12. 648 individuals with USS data 
and 2,034 with ALT/AST levels at age 17 had data for enzyme- 
assessed lipids and glucose at age 15.
We repeated our main analyses with a consistent ‘control’ 
group across all three indicators – i.e. for each indicator we 
compared those having the indicator to those who did not have 
any of the three indicators – in order to make sure that any 
differences were not biased towards the null because of some of 
those without a particular indicator having some hepatic 
steatosis as suggested by one of the other indicators. 1,022 
individuals with data for ALT/AST and USS did not meet any 
criteria for NAFLD and formed the control group for these 
analyses.
Results
Descriptive characteristics of those with USS data for steatosis 
and those with ALT/AST data are summarized in Table 1. 44.2% 
of the USS population and 48.1% of the ALT/AST population 
were male. The mean age of individuals included in our analy-
ses was 17.9 (SD 0.4) years for the USS population and 17.8 
(SD 0.4) years at assessment for the ALT/AST population.
Prevalence of NAFLD by different methods of assessment
The prevalence of NAFLD was similar across the three differ-
ent indicators (2.3%, 3.1% and 2.3%, for USS steatosis, elevated 
ALT (>40 U/l) and elevated AST (>40 U/l), respectively), but 
with varying levels of overlap in cases across the measures. 
Of the 1,088 individuals who had data for all three indicators 
of NAFLD, only three met all three criteria (0.3%), with over-
lap between elevated ALT and elevated AST being greatest. In 
this sample there was no overlap between USS steatosis and 
elevated AST (Figure 3). As we might have expected, the preva-
lence of obesity (BMI > 30kg/m2) was greater in those with each 
indicator of NAFLD, but was greatest for USS steatosis (60%, 
20% and 12% for USS steatosis, elevated ALT and elevated AST, 
respectively, compared to 5% for participants without these 
indicators).
Metabolic profile of NAFLD
Figure 4–Figure 6 present the associations between NAFLD, 
assessed by USS, elevated ALT and elevated AST and each 
of the 154 metabolic traits in SD units, adjusted for age, sex 
and BMI. These results are tabulated in full in Extended data: 
Table 1–Extended data: Table 3, and in original units (mostly 
μmol/l) in Extended data: Table 4–Extended data: Table 6. 
Extended data: Figure 1–Extended data: Figure 3 show the same 
results comparing both model 1 (age- and sex-adjusted) and 
model 2 (age-, sex- and BMI-adjusted); these show that adjust-
ment for BMI did attenuate many associations. The associations 
between each indicator of NAFLD and the VLDL metabolic 
traits were most attenuated after adjustment for BMI, with the 
effect of greatest magnitude for USS steatosis (attenuated by 
approximately 50%) and the weakest magnitude for elevated 
AST. However, even with this adjustment there were wide-
spread associations of NAFLD with multiple metabolic traits, and 
here we focus on the results with adjustment for BMI.
Lipoprotein subclasses. All three indicators of NAFLD were 
associated with higher concentrations of the extremely large, 
very large, large, medium and small VLDL metabolic traits. The 
largest effect sizes were observed between USS steatosis and the 
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Table 1. Characteristics of the study populations.
ALT/AST population USS population
N (total) N (%) N (total) N (%)
Sex (male) 3035 1461 (48.1) 1101 487 (44.2)
USS steatosis 1088 25 (2.3) 1101 25 (2.3)
Elevated ALT (>40U/l) 3035 91 (3.0) 1088 33 (3.0)
Elevated AST (>40U/l) 3035 68 (2.2) 1088 29 (2.7)
Maternal education 2763 1004
    CSE/Vocational  487 (17.6) 196 (19.5)
    O Level  894 (32.4) 332 (33.1)
    A Level and above  1382 (50.0) 476 (47.4)
Ethnicity (White British) 2758 2700 (97.9) 1000 980 (98.0)
N Mean (SD) N Mean (SD) 
Age at ultrasound assessment (years) 3035 17.8 (0.4) 1101 17.9 (0.4)
AUDIT score 2555 6.9 (4.6) 897 6.9 (4.8)
MVPA (mins/day) 1216 24.2 (18.8) 396 22.8 (17.0)
BMI (kg/m2) 3035 22.7 (3.9) 1101 23.0 (4.0)
Energy intake (kcal) 2521 1968.0 (506.2) 844 1953.2 (504.6)
N represents the maximum sample size based on those with complete data for ALT/AST or USS, age, sex, 
BMI and at least one metabolic trait.
Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; USS: ultrasound scan; 
AUDIT: alcohol use disorders identification test; MVPA: moderate to vigorous physical activity; BMI: body 
mass index; SD: standard deviation.
Figure 3. Comparison of three different indicators of NAFLD. 
These analyses were undertaken in 1,088 participants with data that 
allowed all three indicators of NAFLD to be applied. USS (ultrasound 
scan) defined steatosis is evidence of steatosis on ultrasound scan; 
elevated AST (aspartate aminotransferase) is anyone with AST >40 
U/l; elevated ALT (alanine aminotransferase) is anyone with ALT >40 
U/l.
extremely large, very large and large VLDLs, with effect sizes 
ranging from 0.6 to 0.8SD. Elevated ALT was positively related to 
very small VLDL, IDL, and large, medium and small LDL meta-
bolic traits. Effect estimates for USS steatosis and elevated AST 
were closer to the null, apart from triglycerides in these parti-
cles, for which positive associations of a similar magnitude were 
observed for all three indicators. There was evidence of consist-
ent (across all three indicators) negative associations between 
NAFLD and very large and large HDL metabolic traits, except 
for triglycerides in these particles. Associations between all 
indicators of NAFLD and medium and small HDL metabolic 
traits were weakly negative or null, again except triglycerides in 
medium and small HDL, for which positive associations were 
detected. All three indicators were positively associated with 
VLDL particle size and negatively associated with HDL particle 
size. We found no strong evidence for an association between 
any indicator of NAFLD and LDL particle size.
Cholesterol and triglycerides. Elevated ALT was positively asso-
ciated with most cholesterol measures, except for the HDLc 
metabolic traits (HDLc, HDL2c and HDL3c), for which negative 
or null associations were observed. USS steatosis and elevated 
AST were also positively associated with VLDL and remnant 
cholesterol and negatively associated with HDLc and HDL2c. 
Elevated AST was additionally negatively associated with HDL3c. 
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Standardized mean concentrations of all triglycerides were 
higher in those with NAFLD.
Fatty acids. Total fatty acid concentrations were higher in 
individuals with NAFLD, with somewhat larger differences for 
USS steatosis and elevated ALT: effect sizes for USS steato-
sis and elevated ALT were 0.45SD and 0.46SD, respectively, 
compared to 0.23SD for elevated AST. There was some 
evidence for a decreased degree of unsaturation in individuals 
with NAFLD. Monounsaturated and saturated fatty acid concen-
trations were also higher in individuals with NAFLD, although 
evidence for a positive association with percentage of total fatty 
acids was weaker. Linoleic acid, omega-3 (n3), omega-6 (n6) 
and polyunsaturated (PUFA) fatty acid concentrations were 
higher in those with USS steatosis and elevated ALT, but ratio 
of these fatty acids to total fatty acids showed negative (linoleic 
acid, omega-6, PUFA) or null (omega-3) associations with USS 
steatosis and elevated ALT.
Figure 4. Multivariable associations between elevated ALT, elevated AST and ultrasound-assessed steatosis (USS steatosis) and 
standardized metabolic traits. Associations were adjusted for age, sex and BMI. Points represent the difference in mean metabolic trait 
concentrations in standard deviation units for those with NAFLD compared to those without NAFLD (for each of the three indicators). Horizontal 
coloured lines represent 95% confidence intervals. Abbreviations: VLDL: very low density lipoprotein; IDL: intermediate density lipoprotein; 
LDL: low density lipoprotein; BMI: body mass index.
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Figure 5. Multivariable associations between elevated ALT, elevated AST and ultrasound-assessed steatosis (USS steatosis) and 
standardized metabolic traits. Associations were adjusted for age, sex and BMI. Points represent the difference in mean metabolic trait 
concentrations in standard deviation units for those with NAFLD compared to those without NAFLD (for each of the three indicators). Horizontal 
coloured lines represent 95% confidence intervals. Abbreviations: HDL: high density lipoprotein; C: cholesterol; MUFA: monounsaturated fatty 
acid; PUFA: polyunsaturated fatty acid; BMI: body mass index.
Low molecular weight metabolites. Of the low molecular weight 
metabolites, concentrations of the branched-chain and aromatic 
amino acids and the inflammatory marker glycoprotein 
acetyls were higher in those with NAFLD, except for leucine 
and valine in individuals with USS steatosis, for which there 
was no difference in concentration.
Magnitude of associations. Although some magnitudes of asso-
ciations varied slightly between the three indicators of NAFLD, 
and p-values differed due to different sample sizes (smaller 
for USS), overall there was a high level of consistency between 
the three indicators of NAFLD in their associations with the 
metabolic traits, with the goodness of fit between each pair 
(measured using R2) all greater than 0.7 (Figure 7). Furthermore, 
where associations were observed these were large, usually in 
the range of 0.4 to 0.7 SD difference between those with and 
without NAFLD.
Additional analyses
There was almost perfect correspondence between the age, 
sex and BMI, and the age, sex and TBFM–adjusted models 
(R2>0.99; Extended data: Figure 4). Results were the same when 
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Figure 6. Multivariable associations between elevated ALT, elevated AST and ultrasound-assessed steatosis (USS steatosis) and 
standardized metabolic traits. Associations were adjusted for age, sex and BMI. Points represent the difference in mean metabolic trait 
concentrations in standard deviation units for those with NAFLD compared to those without NAFLD (for each of the three indicators). Horizontal 
coloured lines represent 95% confidence intervals. Abbreviations: CRP: C-reactive protein; BMI: body mass index.
individuals with diabetes were excluded and were virtually the 
same when extreme metabolic trait outliers were removed, the 
one exception being an inverse association of elevated ALT 
and elevated AST with acetate when outliers were removed 
(data available on request). Results were also consistent when all 
indicators were compared to a consistent group without any of 
the three indicators of NAFLD (Extended data: Figure 5).
Results were largely the same between NMR- and enzyme- 
assessed total triglycerides, HDLc, LDLc and glucose (Extended 
data: Figure 6). USS steatosis and elevated ALT were positively 
associated with insulin, and elevated ALT and AST positively 
associated with CRP, although these were imprecisely estimated 
with wide CIs (Figure 6). We found no strong evidence that 
enzyme-assessed triglycerides, LDLc or glucose concentra-
tions at age 15 were associated with subsequent NAFLD at age 
17; HDLc at 15 was inversely associated with NAFLD at 17 
and insulin at 15 was positively associated with odds of USS 
steatosis and elevated ALT at 17 (Figure 8).
Discussion
We have found evidence for a disrupted metabolic profile in 
adolescents with evidence of NAFLD, including consistent 
associations of NAFLD, using three different indicators, with 
an adverse lipoprotein and lipid profile. This adverse lipid and 
lipoprotein profile was characterized by increased concentra-
tions of all metabolic traits in the extremely large to small VLDL 
subclasses, all triglycerides, remnant cholesterol and saturated 
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fatty acids. We also found increased concentrations of glyco-
protein acetyls, which are considered to be a stable marker of 
chronic inflammation40 and have been shown to associate with 
cardiovascular disease in several independent adult cohorts29. 
These associations were present with adjustment for general adi-
posity by either BMI or DXA-determined TBFM. Magnitudes 
of association were generally larger for USS steatosis, particularly 
for the larger VLDL metabolic traits, though given the smaller 
sample size for analyses with USS steatosis, the confidence 
intervals were wider. A possible stronger association with USS 
steatosis may reflect the fact that it is likely to be measuring 
more severe NAFLD41.
To the best of our knowledge, this is the first study to determine 
the metabolic profile of NAFLD in a large population of appar-
ently healthy adolescents. Our results highlight the possibility 
Figure 7. Correspondence between indicators of NAFLD. Each point represents a metabolic trait and the position represents the standardized 
mean difference for those with NAFLD as indicated by USS steatosis ((a) and (b)) or elevated AST (c) on the y-axis and those with NAFLD 
indicated by elevated ALT ((a) and (c)) or elevated AST (b) on the x-axis. These estimates were adjusted for age, sex and BMI. Horizontal grey 
lines represent confidence intervals for x-axis associations, and vertical grey lines represent confidence intervals for y-axis associations. The 
red dashed line represents the regression line between x-axis and y-axis associations for each metabolic trait. R2 indicates goodness-of-fit. A 
slope of 1 with an intercept of 0 (grey dashed line) and all dots sitting on that line (R2 = 1) would indicate exact correspondence, in terms of 
direction and magnitude, between associations of the pair of indicators of NAFLD with metabolic traits. Abbreviations: USS: ultrasound scan; 
ALT: alanine aminotransferase; AST: aspartate aminotransferase.
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that NAFLD at this young age is potentially already having 
adverse consequences that might increase the future risk of 
diabetes and cardiovascular disease. Our findings have some 
consistency with findings from an adult cohort (the Young Finns 
study) that used the same NMR platform, including strong 
positive associations with extremely large to small VLDL particle 
concentrations and glycoprotein acetyls20. In contrast to our study, 
USS steatosis in that adult cohort was also associated with small 
HDL particle concentration, CRP, glucose, lactate and pyruvate, 
and the magnitudes of associations with amino acids were 
stronger than we found. Associations with a wider-range of 
metabolic traits in the adult cohort might reflect a greater accu-
mulation of NAFLD risk factors and longer exposure to NAFLD 
with greater age, but this requires further analyses in inde-
pendent cohorts with repeat metabolomic measurements at 
different ages.
Figure 8. prospective associations between enzyme-assessed cardiometabolic risk factors at average age 15 and indicators of 
NAFLD at average age 17. Associations were adjusted for age, sex and BMI. Points represent the odds ratio for NAFLD (for each of the 
three indicators) per standard deviation increase in cardiometabolic risk factor concentration. Bars represent 95% confidence intervals. 
Abbreviations: HDLc: high density lipoprotein cholesterol; LDLc: low density lipoprotein cholesterol; ALT: alanine aminotransferase; AST: 
aspartate aminotransferase; USS: ultrasound scan.
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The Young Finns study, although mostly based on cross- 
sectional analyses, examined associations of metabolic profiles 
with subsequent occurrence of USS steatosis. In contrast, given 
the role of the liver in multiple metabolic pathways, we hypoth-
esized that accumulation of liver fat would precede any alterations 
in metabolic profile and we therefore treated NAFLD as 
the exposure in our analyses. As our analyses were cross- 
sectional, we are unable to assess temporality. However, we 
found little evidence that enzyme-assessed fasting total triglyc-
erides, LDLc, glucose or CRP at age 15 were associated with 
subsequent NAFLD at 17, providing evidence for liver fat accu-
mulation preceding metabolic disruption. The largest effect sizes 
we observed were for the VLDL traits; given the role of the liver 
in assembly and secretion of VLDLs, our hypothesized causal 
direction is further justified.
The strengths of this study are its large sample size, the abil-
ity to adjust for BMI or fat mass and the exploration of a wide 
range of metabolic traits using an NMR platform that is 
highly reproducible30.
Liver biopsy is considered the gold-standard methodology to 
diagnose NAFLD but would be unethical to use in a popula-
tion of healthy adolescents. Liver biopsy may also miss liver 
fat because of sampling variability, as only a small sample of 
liver is selected42. The EASL-EASD-EASO guidelines recom-
mend USS for the diagnosis of steatosis but a biopsy is required 
for the presence of NASH43. Therefore, our study is unable to 
draw any conclusions about differences in metabolic profiles of 
those with NASH. Reliability and accuracy of USS, compared 
to biopsy, has been demonstrated for moderate to severe fatty 
liver44. However, USS assessment of steatosis is less sensitive 
when liver fat accumulation is <30%41 and in obese individuals45, 
who have a greater risk of developing NAFLD2,10, yet our results 
were consistent across three different indicators of NAFLD 
and we adjusted for BMI or TBFM in our regression model. 
There is currently no consensus for the ALT/AST threshold to 
indicate NAFLD. A systematic review of prevalence of NAFLD 
in children and adolescents identified that ALT was by far the 
most common enzyme used to identify NAFLD, with a thresh-
old of 40U/l most commonly used. AST was used in just one 
of the studies, again with a threshold of 40U/l used to identify 
NAFLD2. We are not aware of a study comparing the sensitivity or 
specificity of this threshold to biopsy-diagnosed disease in a gen-
eral population as here. Our population was 98% white British, 
limiting generalizability to adolescents of other ethnicities. 
Some of our results had wide CIs (particularly the associations 
between USS steatosis and the metabolic traits) and although our 
findings were mostly consistent with those from one previous 
study in adults, we are not aware of any other study with data 
on NAFLD and a wide range of metabolic traits that could be 
used to replicate our findings in healthy adolescents.
In conclusion,this study provides evidence that NAFLD in ado-
lescence is already associated with widespread adverse lipid 
and fatty acid profiles, and with the inflammatory biomarker 
glycoprotein acetyls. These findings are important as they imply 
adverse profiles, that in adults are related to risk of cardiovascu-
lar disease29, are apparent in early life. Follow-up data collection 
in this population will allow prospective analysis to determine 
if these differences persist into adulthood, which would 
further imply their potential role in mediating the impact of 
adolescent NAFLD on future adverse cardiovascular disease. 
Thus, our findings provide the foundations for further research 
exploring causal relations between adolescent NAFLD and 
widespread metabolic disruption, that potentially persists and 
could result in increased cardiovascular risk.
Data availability
Underlying data
ALSPAC data access is through a system of managed open 
access. The steps below highlight how to apply for access to the 
data included in this data note and all other ALSPAC data. The 
datasets presented in this article are linked to ALSPAC project 
number B1032, please quote this project number during your 
application. The ALSPAC variable codes highlighted in the 
dataset descriptions can be used to specify required variables.
1. Please read the ALSPAC access policy (PDF, 627kB) 
which describes the process of accessing the data and samples in 
detail, and outlines the costs associated with doing so.
2. You may also find it useful to browse our fully searchable research 
proposals database, which lists all research projects that have 
been approved since April 2011.
3. Please submit your research proposal for consideration by the 
ALSPAC Executive Committee. You will receive a response 
within 10 working days to advise you whether your proposal 
has been approved.
If you have any questions about accessing data, please email 
alspac-data@bristol.ac.uk.
The ALSPAC data management plan describes in detail the 
policy regarding data sharing, which is through a system of 
managed open access.
The study website also contains details of all the data that is 
available through a fully searchable data dictionary: http://www.
bristol.ac.uk/alspac/researchers/data-access/data-dictionary/.
Extended data
Extended data table and figures are available via the Open Sci-
ence Framework: Metabolic profiling of adolescent non-alcoholic 
fatty liver disease, https://doi.org/10.17605/OSF.IO/SNA6C46.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Table 1. Age, sex and BMI adjusted associations between USS-
assessed steatosis and metabolic traits in standard deviation 
units.
Table 2. Age, sex and BMI adjusted associations between elevated 
ALT and metabolic traits in standard deviation units.
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Table 3. Age, sex and BMI adjusted associations between elevated 
AST and metabolic traits in standard deviation units.
Table 4. Age, sex and BMI adjusted associations between USS-
assessed steatosis and metabolic traits in molar concentrations.
Table 5. Age, sex and BMI adjusted associations between 
elevated ALT and metabolic traits in molar concentrations.
Table 6. Age, sex and BMI adjusted associations between 
elevated AST and metabolic traits in molar concentrations.
Figure 1. Multivariable associations between USS-assessed 
steatosis and 154 metabolic traits.
Figure 2. Multivariable associations between elevated ALT and 
154 metabolic traits.
Figure 3. Multivariable associations between elevated AST and 
154 metabolic traits.
Figure 4. Correspondence between models adjusted for age, 
sex and BMI and models adjusted for age, sex and total body fat 
mass (TBFM) for each indicator of NAFLD.
Figure 5. Correspondence between results of analyses where 
the control group was indicator specific (i.e. did not meet the 
criteria for NAFLD based on one indicator only) and results 
where the control group did not meet the criteria for NAFLD 
based on all three indicators.
Figure 6. Comparison of multivariable associations between 
indicators of NAFLD, and non-NMR-assessed and NMR- 
assessed cardiometabolic risk factors.
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Summary
Hartley and colleagues report associations between NAFLD and 154 different plasma metabolites (mainly
lipoproteins and amino acids) among 3048 children and adolelescents from the ALSPAC cohort. NAFLD
was assessed by 1) ultrasound, 2) elevated alanine aminotransferase levels, or 3) elevated aspartate
aminotransferase levels. The main finding of the study was that NAFLD was associated with pervasive
changes in plasma metabolites, with the most robust effect seen for plasma VLDL.
Strengths
1) The metabolic characterization is comprehensive.
2) The statistical methods are meticulous and state-of-the art.
3) There are few large cohorts of well-characterized children and adolescents with measurements of
NAFLD available. The study adds substantially to the NAFLD literature. 
4) It is interesting (and new) to see the 'metabolic fingerprints' of ultrasound- vs ALT- vs AST-defined
NAFLD.
Weaknesses
1) The main weakness relates to the use of nonspecific and nonsensitive methods to assess NAFLD.
Ultrasound is a relatively imprecise method to assess liver fat with, especially in those with low levels of
liver fat (like almost all individuals in the present study). Elevated ALT and/or AST also have low sensitivity
and specificity for detecting NAFLD. This limitation is acknowledged in the paper.
One way of addressing this weakness could be to show the association of the 3 NAFLD-phenotypes with
PNPLA3 I148M, a strong and specific genetic risk factor for NAFLD. If US-, ALT, and AST-defined NAFLD
truly reflects NAFLD in this cohort, they should also associate with PNPLA3 I148M. In other words
PNPLA3 I148M could be used a 'genetic positive control'. 
Is the work clearly and accurately presented and does it cite the current literature?
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Is the study design appropriate and is the work technically sound?
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Are sufficient details of methods and analysis provided to allow replication by others?
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If applicable, is the statistical analysis and its interpretation appropriate?
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Are all the source data underlying the results available to ensure full reproducibility?
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Are the conclusions drawn adequately supported by the results?
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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 Warwick B. Dunn
School of Biosciences, University of Birmingham, Birmingham, UK
The manuscript submitted details a NMR-based metabolic profiling study of NAFLD in adolescents of
approximate age 17. The manuscript was descriptively written to allow the reader to understand the
methods applied and to be able to repeat the work and was also written to easily understand the major
conclusions.
 
The strengths of the manuscript are as follows:
1. The cohort studied (ALSPAC) was highly appropriate as the recruited subjects are highly characterised
and phenotyped at different ages. This cohort also provides the possibility for subject follow-up in the
future.
2. The study of NAFLD in young adults is novel and innovative. NAFLD can develop and remain as a
human ages or can develop in to more serious diseases. The ability to stratify subjects at early stages of
NAFLD and provide follow-up in 5 and 10 years time will be innovative and provide more information on
how NAFLD develops in to more serious conditions.
3. The metabolic profiling approach used were highly appropriate and is highly proven in these types of
studies. The approach provides data on different aspects of metabolism including lipoproteins, lipid
metabolism and branched chain amino acids; all of these have been defined as important in human
ageing and disease. All data is also quantitative and so is comparable to other datasets which were
acquired applying the same approach.
4. The results clearly show the association between early NAFLD and many of the 154 metabolic traits
measured and raises some interesting questions to be studied further in follow-up.
The weaknesses of the manuscript are as follows:
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 The weaknesses of the manuscript are as follows:
1. The use of two liver enzymes as markers of NAFLD was interesting as these enzymes are not specific
to NAFLD but are more general markers of liver health/disease and are associated with different liver
diseases. Inclusion of a discussion as to why these two measures were included and why they differ in
magnitude to steatosis measures would have benefited the manuscript. Construction of the manuscript
with a focus on ultrasound steatosis measures would have allowed easier understanding.
2. Replication in an independent cohort would have increased the confidence in the generalisability of the
conclusions provided, though I am unaware of a cohort to be able to apply for replication.
3. The metabolic profiling approach of NMR spectroscopy is a strength for understanding specific areas
of metabolism but the lack of inclusion of other metabolic profiling approaches to complement the NMR
data is a weakness and should be considered for future work. The inclusion of UPLC-MS to investigate
the same plasma samples would be appropriate to provide information on a wide number of metabolites
and metabolic pathways; for example, lipidomic analysis would provide greater information on the
individual lipids in each lipid class whereas NMR only provides a single measure which integrates all of
the separate lipids.
 
Overall, the manuscript provides robust data and biological conclusions and opens up some interesting
biological questions requiring further study in the future.
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